Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eva Hellström-Lindberg

Showing results (1-10 of 164) with videos related to

Pageof 17
Sort By:
Current Hematology Reports|August 7, 2003
Approach to anemia associated with myelodysplastic syndromesEva Hellström-Lindberg
Current Drug Targets|September 24, 2005
Strategies for biology- and molecular-based treatment of myelodysplastic syndromesEva Hellström Lindberg
Blood Reviews|February 23, 2010
Significance of JAK2 and TET2 mutations in myelodysplastic syndromesEva Hellström-Lindberg
Hematology. American Society of Hematology. Education Program|November 24, 2005
Update on supportive care and new therapies: immunomodulatory drugs, growth factors and epigenetic-acting agentsEva Hellström-Lindberg
Hematology. American Society of Hematology. Education Program|December 17, 2008
The role of JAK2 mutations in RARS and other MDSEva Hellström-Lindberg, Mario Cazzola
Seminars in Hematology|January 9, 2008
Supportive care and use of hematopoietic growth factors in myelodysplastic syndromesEva Hellström-Lindberg, Luca Malcovati
Experimental Cell Research|March 10, 2010
New clues to the molecular pathogenesis of myelodysplastic syndromesMartin Jädersten, Eva Hellström-Lindberg
Blood Reviews|December 11, 2007
Supportive care, growth factors, and new therapies in myelodysplastic syndromesEva Hellström-Lindberg, Luca Malcovati
Haematologica|December 14, 2004
Hypochromic red blood cells in low-risk myelodysplastic syndromes: effects of treatment with hemopoietic growth factorsTherese Ljung, Rune Bäck, Eva Hellström-Lindberg
Best Practice & Research. Clinical Haematology|February 11, 2014
Erythropoiesis stimulating agents and other growth factors in low-risk MDSEva Hellström-Lindberg, Arjan van de Loosdrecht
Pageof 17

Showing results (1-10 of 164) with videos related to

Sort By:
Pageof 17
Current Hematology Reports|August 7, 2003
Approach to anemia associated with myelodysplastic syndromesEva Hellström-Lindberg
Current Drug Targets|September 24, 2005
Strategies for biology- and molecular-based treatment of myelodysplastic syndromesEva Hellström Lindberg
Blood Reviews|February 23, 2010
Significance of JAK2 and TET2 mutations in myelodysplastic syndromesEva Hellström-Lindberg
Hematology. American Society of Hematology. Education Program|November 24, 2005
Update on supportive care and new therapies: immunomodulatory drugs, growth factors and epigenetic-acting agentsEva Hellström-Lindberg
Hematology. American Society of Hematology. Education Program|December 17, 2008
The role of JAK2 mutations in RARS and other MDSEva Hellström-Lindberg, Mario Cazzola
Seminars in Hematology|January 9, 2008
Supportive care and use of hematopoietic growth factors in myelodysplastic syndromesEva Hellström-Lindberg, Luca Malcovati
Experimental Cell Research|March 10, 2010
New clues to the molecular pathogenesis of myelodysplastic syndromesMartin Jädersten, Eva Hellström-Lindberg
Blood Reviews|December 11, 2007
Supportive care, growth factors, and new therapies in myelodysplastic syndromesEva Hellström-Lindberg, Luca Malcovati
Haematologica|December 14, 2004
Hypochromic red blood cells in low-risk myelodysplastic syndromes: effects of treatment with hemopoietic growth factorsTherese Ljung, Rune Bäck, Eva Hellström-Lindberg
Best Practice & Research. Clinical Haematology|February 11, 2014
Erythropoiesis stimulating agents and other growth factors in low-risk MDSEva Hellström-Lindberg, Arjan van de Loosdrecht
Pageof 17